Its CEO died. The company scrapped a promising program. Now, for their 2nd act.

When Amy Burroughs stepped in as CEO of Terns Pharmaceuticals last February, she joined the company at a challenging time.

Just weeks earlier, Terns announced it was scrapping its phase 2 candidate for metabolic dysfunction-associated steatohepatitis due to changes in the market, despite positive data.